Core Insights - The company reported fourth quarter revenue of $0.7 billion, with a GAAP net loss of $(0.8) billion and a GAAP EPS of $(2.11) [1] - For the full year, revenue was $1.9 billion, with a GAAP net loss of $(2.8) billion and a GAAP diluted EPS of $(7.26) [1] - The company reiterated its plan to achieve up to 10% revenue growth and reduce GAAP operating expenses by 2026 [1] Regulatory and Clinical Updates - The company announced that its influenza vaccine filing has been accepted for regulatory review in the EU, Canada, and Australia; however, it received a Refusal-to-File letter from the U.S. FDA and has requested a Type A meeting to clarify the path forward [1] - The Norovirus Phase 3 trial is fully enrolled, with data readout expected in 2026 [1] - Full enrollment of the Phase 2 intismeran autogene trial in muscle invasive bladder cancer has been achieved [1] Business Developments - In 2025, the company focused on sharpening its commercial execution, launched its third product, and brought online three international manufacturing sites while advancing its mRNA pipeline [1]

TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announces that Mr. Richard Sutin and Mr. Angelos Georgakis have been appointed, effective as of February 12, 2026, to the board of directors of the Company (the “Board”). “We are excited to welcome Mr. Richard Sutin and Mr. Angelos Georgakis to the Medicenna board of directors” commented ...

Core Viewpoint - Immunic, Inc. has announced an oversubscribed private placement of up to USD 400 million to facilitate its transition into a commercial-stage company, focusing on the development of novel oral therapies for neurologic diseases, particularly multiple sclerosis [1][2]. Financing Details - The private placement will provide upfront proceeds of USD 200 million, with the potential for an additional USD 200 million through warrants [1][2]. - The financing was led by existing investor BVF Partners L.P. and included participation from various institutional investors [1][2]. - The company plans to use the net proceeds to fund clinical trials, operations, and general corporate purposes, with expectations to support activities through late 2027 [2]. Clinical Development Plans - Immunic aims to initiate a Phase 3 clinical program for primary progressive multiple sclerosis (PPMS) later this year, which is expected to take approximately 3.5 to 4 years to complete [1]. - The ongoing Phase 3 ENSURE trials for vidofludimus calcium in relapsing multiple sclerosis (RMS) are expected to yield top-line data by the end of 2026, with a New Drug Application (NDA) submission planned for mid-2027 [1][2]. Product Mechanism and Potential - Vidofludimus calcium is designed to provide neuroprotective effects and reduce inflammatory damage, addressing key biological drivers of disability progression in multiple sclerosis [1]. - The drug's mechanism involves enhancing neuronal survival through nuclear receptor-related 1 (Nurr1) activation and selective inhibition of dihydroorotate dehydrogenase (DHODH) [1]. Leadership Changes - Dr. Daniel Vitt, the co-founder and CEO, will transition to a new role focused on scientific strategy, while the search for a new CEO with commercial expertise in the MS space is underway [1][2]. - Simona Skerjanec has been appointed as the interim Chairperson of the Board of Directors, bringing significant experience from her previous role at Roche [1][2].

Core Viewpoint - Genmab A/S is highlighted as a high-growth international stock, with a strong buy rating and a price target of $39 following significant sales growth of DARZALEX in 2025 [1]. Group 1: Sales Performance - In 2025, worldwide net sales of DARZALEX reached $14.351 billion, an increase from $11.670 billion in 2024, representing a growth of approximately 22.9% [2]. - The US contributed over half of the sales, amounting to around $8.266 billion, while the rest of the world accounted for $6.085 billion [2]. Group 2: Royalty Revenue - Genmab does not sell DARZALEX directly but earns royalties from Johnson & Johnson, receiving $2.219 billion in total royalty revenue during the first nine months of 2025, up from $1.802 billion in the same period of 2024, marking a 23% year-over-year increase [4]. - Management had initially estimated full-year DARZALEX royalties to be between $2.3 billion and $2.4 billion, based on projected net sales of $13.7 billion to $14.1 billion, but actual sales exceeded expectations, indicating royalties will likely surpass $2.4 billion [5]. Group 3: Company Overview - Genmab A/S is a Denmark-based biotechnology company focused on developing antibody therapeutics for cancer treatment, co-developing drugs like DARZALEX, Kesimpta, and TEPEZZA, and earning royalties through licenses to partners such as Johnson & Johnson [6].

Core Insights - Ultragenyx has successfully launched four rare disease treatments but has not yet achieved profitability, reporting a net loss of $575 million against full-year revenue of $673 million [3] - The company aims to reach profitability by 2027, although recent setbacks have altered revenue growth expectations [3] Drug Development and Regulatory Challenges - A drug co-developed with Mereo Biopharma failed a Phase 3 trial for osteogenesis imperfecta, and the gene therapy UX111 for Sanfilippo syndrome Type A was rejected by the FDA due to manufacturing concerns [4] - The FDA's rejection of UX111 has created uncertainty regarding biomarker-based approvals in rare diseases and gene therapy, impacting revenue outlook [5] Corporate Restructuring and Financial Projections - Ultragenyx plans to cut 130 jobs, representing 10% of its workforce, as part of a restructuring aimed at supporting profitability by 2027 [6] - The restructuring is expected to keep expenses flat or slightly reduced in 2026, with a projected 15% decrease in expenses by 2027 compared to 2025 [6] - The company anticipates revenue growth of 8 to 13 percent for the current year, despite analysts reducing share price targets due to longer approval timelines [6]

Core Insights - The article highlights the economic growth of various cities in China, particularly focusing on Shenzhen, which has seen significant GDP increases and the emergence of new "trillion-yuan cities" [1][3]. Economic Growth and City Rankings - The number of cities with a GDP exceeding 1 trillion yuan is set to increase from 27 in 2024 to 29 in 2025, with Wenzhou and Dalian making the list [1]. - Beijing has joined the ranks of "5 trillion cities," while Shenzhen leads the four first-tier cities with a growth rate of 5.5%, aiming for a GDP exceeding 5 trillion yuan by 2025 [1]. District Performance in Shenzhen - Nanshan District has achieved a GDP of 10,102.38 billion yuan, becoming the first district in China to surpass the trillion-yuan mark [3][5]. - Futian and Longgang districts are also significant, with Futian's GDP reaching 6,420.22 billion yuan and Longgang expected to exceed 6,000 billion yuan [2][9]. - Nanshan contributes over 25% of Shenzhen's total economic output despite its small area of 185 square kilometers [3]. GDP Growth Rates - Among the districts, Pingshan (10.5%) and Shenshan (10.3%) have shown remarkable growth rates, focusing on high-value industries such as automotive and pharmaceuticals [10][11]. - The overall GDP of Shenzhen is projected to reach 38,731.8 billion yuan by 2025, with several districts outperforming the city average [2][10]. Sectoral Contributions - Nanshan is home to over 200 listed companies, contributing significantly to Shenzhen's economy, with a total market value expected to exceed 65 trillion yuan by 2025 [5][6]. - Futian's modern service sector is projected to grow, with a value of 4,754.98 billion yuan, accounting for 82.2% of its tertiary industry [6][7]. Industrial Focus and Innovation - Pingshan is concentrating on developing a "6+3" industrial cluster, focusing on smart connected vehicles, semiconductors, and biomedicine, with strategic emerging industries expected to account for 88% of its industrial output [11][12]. - The Shenshan Special Cooperation Zone is also leveraging the presence of BYD to enhance its automotive industry, with multiple projects set to launch by 2025 [12][13].

Core Insights - Moderna reported better-than-expected fourth quarter sales and affirmed revenue growth estimates for 2026 despite soft demand for its COVID-19 vaccine and pushback from the FDA [1] Financial Performance - The company recorded revenue of $678 million in Q4 2025 and $1.9 billion for the entire year, figures at the higher end of projections [2] - U.S. sales more than halved between Q3 and Q4 but still accounted for over 60% of full-year revenue, aided by the launch of the COVID shot mNEXSPIKE and a strong retail market [2] Future Growth Projections - Moderna reiterated a predicted growth of 10% in 2026, primarily from international markets, accounting for a decline in COVID vaccinations and no revenue from influenza or combination shots [3] Regulatory Challenges - The combination shot and standalone flu vaccine are under review in international markets but face regulatory challenges in the U.S. [4] - Moderna received a "refuse-to-file" letter for its flu vaccine, mRNA-1010, due to issues with the comparator used in its Phase 3 trial [5] - The company has requested a Type A meeting with the FDA to discuss the decision regarding mRNA-1010 [5][6] Analyst Sentiment - Analysts express caution, with RBC Capital Markets noting skepticism about the FDA reversing its decision, while Leerink Partners views the FDA letter as indicative of pressure from current leadership [7] Market Access Advocacy - Moderna's president emphasized the importance of American seniors having access to innovations similar to other markets, highlighting the need for advanced mRNA technologies in influenza vaccine development [8]

Core Insights - Neurocrine Biosciences (NBIX) has successfully demonstrated its business development strategy in 2025, leading to optimism for the company as it enters the first quarter of 2026 [1] Company Performance - The company is positioned in high-growth sectors that are expected to experience exponential expansion [1] - There is a strong focus on disruptive technologies and forward-thinking enterprises, indicating a commitment to innovation [1] Investment Strategy - The approach taken by the company combines fundamental analysis with future trend predictions, aiming to leverage innovation for substantial returns [1]

Core Insights - Neurocrine Biosciences (NBIX) has successfully demonstrated its business development strategy in 2025, leading to optimism for the company as it enters the first quarter of 2026 [1] Company Performance - The company is positioned in high-growth sectors that are expected to experience exponential expansion [1] - There is a strong focus on disruptive technologies and forward-thinking enterprises, indicating a commitment to innovation [1] Investment Strategy - The approach taken by the company combines fundamental analysis with future trend predictions, aiming to leverage innovation for substantial returns [1]

Core Insights - Recently, Ruizhi Pharmaceutical and Megia Technology officially signed a strategic cooperation agreement aimed at "building an intelligent biomanufacturing ecosystem to lead industry transformation" [1] - The collaboration will leverage Megia's AI-Agent technology and Ruizhi's advanced preclinical research capabilities along with high-quality data assets to create an "AI-driven automated laboratory for biomedicine" that is both evolvable and deployable [1] - This partnership marks a new phase in the evolution of AI from being an auxiliary tool to becoming a core infrastructure, systematically enhancing the quality and efficiency of drug development and establishing a benchmark project for AI automation in innovative drug research [1]